OncoMatch/Clinical Trials/NCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Is NCT07114315 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including AK112 and AK130 for pancreatic cancer.
Treatment: AK112 · AK130 — This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: TGF-β inhibitor
Prior systemic therapy with either TGF-β inhibitors or anti-angiogenic agents.
Cannot have received: anti-angiogenic agent
Prior systemic therapy with either TGF-β inhibitors or anti-angiogenic agents.
Lab requirements
Blood counts
Kidney function
Liver function
Has adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07114315 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TGF-β inhibitor, anti-angiogenic agent disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages